EP 1289559 B1 20050727 - COMBINATIONS OF ENZYME INHIBITOR-CONTAINING PREPARATIONS AND THE USE THEREOF
Title (en)
COMBINATIONS OF ENZYME INHIBITOR-CONTAINING PREPARATIONS AND THE USE THEREOF
Title (de)
KOMBINATIONEN VON ENZYMINHIBITOREN UMFASSENDE ZUBEREITUNGEN UND DEREN VERWENDUNG
Title (fr)
PREPARATIONS CONTENANT DES COMBINAISONS D'INHIBITEURS ENZYMATIQUES, ET LEURS UTILISATIONS
Publication
Application
Priority
- DE 10025464 A 20000523
- EP 0105887 W 20010522
Abstract (en)
[origin: WO0189569A1] The invention relates to a method which permits, owing to the simultaneous and joint inhibition of the enzyme activities of (I) alanyl-aminopeptidase and dipeptidyl-peptidase IV, (II) of the dipeptidyl-peptidase IV and the angiotensin-converting enzyme, (III) of the dipeptidyl-peptidase IV and prolyl-oligopeptidase, and of (IV) the dipeptidyl-peptidase IV and the X-Pro-aminopeptidase, to inhibit DNA synthesis and thus the proliferation of mononuclear cells as well as of T cells to an extent which cannot be obtained by the individual application of said enzyme inhibitors even when used in higher doses. Although the above-mentioned inhibitors influence the same process, namely DNA synthesis and thus the proliferation of immune cells, this effect is not complete and not long-lasting when the inhibitors are used individually. The functional overlapping of the enzymatic activities results, as is supported by the experimental data, in an additive/super-additive inhibitory effect on DNA synthesis and the proliferation resulting from the simultaneous inhibition of a plurality of the above enzymes. The invention shows that the simultaneous application of inhibiting substances of the above-mentioned enzymes or of corresponding preparations and forms of administration is suitable for the therapy of autoimmune diseases and chronic diseases with an inflammatory genesis as well as for the treatment of post-transplant rejection episodes.
IPC 1-7
IPC 8 full level
A61K 31/40 (2006.01); A61K 31/401 (2006.01); A61K 31/4164 (2006.01); A61K 31/425 (2006.01); A61K 31/445 (2006.01); A61K 31/4453 (2006.01); A61K 38/55 (2006.01); A61K 45/06 (2006.01); A61P 1/04 (2006.01); A61P 3/10 (2006.01); A61P 7/06 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP US)
A61K 38/55 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 1/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 7/06 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
C-Set (source: EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0189569 A1 20011129; AT E300313 T1 20050815; AU 2001267475 B2 20041104; AU 6747501 A 20011203; CA 2410305 A1 20021122; CA 2410305 C 20100202; CN 1430519 A 20030716; DE 10025464 A1 20011206; DE 50106906 D1 20050901; DK 1289559 T3 20051114; EP 1289559 A1 20030312; EP 1289559 B1 20050727; EP 1289559 B8 20050928; ES 2243516 T3 20051201; JP 2003534293 A 20031118; JP 4965787 B2 20120704; US 2005014699 A1 20050120; US 7485626 B2 20090203
DOCDB simple family (application)
EP 0105887 W 20010522; AT 01945184 T 20010522; AU 2001267475 A 20010522; AU 6747501 A 20010522; CA 2410305 A 20010522; CN 01810023 A 20010522; DE 10025464 A 20000523; DE 50106906 T 20010522; DK 01945184 T 20010522; EP 01945184 A 20010522; ES 01945184 T 20010522; JP 2001585811 A 20010522; US 29610204 A 20040326